Blue Origin’s New Glenn rocket at liftoff during the NG-2 mission on Nov. 13. Credit: Blue Origin The U.S. Space Force is now taking proposals from new launch providers with rockets ready to fly by ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking ...

TPAO has awarded additional contracts for additional development of Sakarya gas field in the Black Sea. Phase 3 involves a new floating production unit, 27 wells, and a 183-km export pipeline ...

The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain ...

aTyr Pharma is a small-cap biotech focused on Efzofitimod for interstitial lung disease (ILD), a group of lung-scarring diseases. In 2021, the company completed a phase 1b/2a trial in pulmonary ...

HONOLULU (KHON2) — Hawaii’s largest infrastructure project is taking another big step, as the project broke ground on the next phase of the Skyline rail project. Around the clock testing starts for ...

Launching a new MMORPG against the long-established giants is a daunting prospect. World of Warcraft, FF14, Guild Wars 2, Runescape, Eve Online; the list goes on, making it a tough task to craft a ...

Ambitious MMORPG Ashes of Creation is gearing up for the next stage of its ongoing alpha test, and there's a lot to look forward to. In a new development livestream, Intrepid Studios reveals a big ...

A SpaceX Falcon 9 rocket launched June 25 from Cape Canaveral Space Force Station on the Starlink 10-16 mission. Credit: SpaceX The U.S. Space Force has awarded SpaceX the latest task order under its ...

In a prespecified analysis of a phase 3 trial, sibeprenlimab halved proteinuria in adults with IgA nephropathy. Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy ...